Standard Operating Procedure Title: Initial Investigation of Out of Specification (OOS) Results in Microbiological Laboratory

Size: px
Start display at page:

Download "Standard Operating Procedure Title: Initial Investigation of Out of Specification (OOS) Results in Microbiological Laboratory"

Transcription

1 Department Micro Laboratory Document no MICLAB 145 Title 1.0 DOCUMENT OWNER Laboratory/Quality Manager 2.0 PURPOSE To establish a procedure for the investigation of initial out-of-specification (OOS) or questionable results which have been generated for the product or material being tested. 3.0 SCOPE Initial Investigation of Out of Specification (OOS) Results in Microbiological Laboratory Prepared by: Date: Supersedes: Checked by: Date: Date Issued: Approved by: Date: Review Date: 3.1 This procedure applies to test results generated for raw materials, in-process materials, stability and finished products tested for medicinal products for commercial sale. 3.2 This procedure applies to test results generated for release, stability, in-process and retained samples associated with a complaint investigation. 3.3 This procedure does not apply to results generated by testing not described in 3.1 or 3.2 or out of specification results for process water and environmental samples. 3.4 An investigation for out-of-specification or questionable results must be initiated when an analysis has been performed on the sample in question. 3.5 Instances of out-of-specification or questionable results, where assignable cause is not readily apparent shall be investigated in accordance with the requirements described in this procedure. 3.6 If assignable cause is readily apparent, the occurrence is documented using the Laboratory Investigation Report (LIR) form, as applicable. 3.7 All LIR s must be completed and fully approved within 30 business days of the discovery of the initial OOS or questionable result. If laboratory investigation goes beyond 30 business days, an interim status report must be issued to the QA Manager. 3.8 All LIR s should be reviewed once per year to determine if trends are observed that require further action strictly prohibited. Page 1 of 11

2 4.0 RESPONSIBILITY \ BUSINESS RULES 4.1 Quality Assurance Manager is responsible for: - Reviewing laboratory investigations and considering in batch/lot release decisions. - Approval re-sampling programs of materials for use in the laboratory investigation. - Issuing Action reports to appropriate personnel when deemed necessary. - Evaluate the need for investigations where confirmed out-of-specification results occur and ensuring they are completed. - Approving laboratory investigations on completion. 4.2 Laboratory Manager is responsible for: - Ensuring that this SOP is understood and adhered to by all laboratory personnel. - Establishing and maintaining a log of all laboratory reports. - Where appropriate notifying the QA Manager to instigate further investigation where confirmed out-of-specification results are produced. - Reports trends of Microbiology Laboratory Investigations to the QA Manager on a periodic basis. - Complete final review of the Laboratory Investigation Report. - Review LIR s once a year, observe trends and take action if applicable. 4.3 Microbiology Team Leader is responsible for: - Reviewing and approving the applicable sections for the laboratory investigation report. - Approving investigation measurements and re-testing plans. - Ensuring laboratory investigation reports, all results and laboratory records are achieved. - Responsible for closing out LIR in database for tracking and trending purposes. - Responsible for circulating the Alert Reports. - Assisting the Laboratory Analyst in the completion of the Microbiology Laboratory Investigation Report. 4.4 Microbiological Analyst: - Immediately notifying the Microbiology Team Leader or Laboratory Manager of any out-ofspecification or questionable result. - Initiating and assisting in the completion of the Laboratory Investigation Report. - Including all data generated in the laboratory investigation report. strictly prohibited. Page 2 of 11

3 - Immediately notifying the Microbiology Team Leader or the Lab Manager of any microbiological test result which does not meet specification or which fits the description of a questionable test result. 5.0 PROCEDURE 5.1 Discovery of out-of-specification or questionable result Upon discovery of any OOS or Questionable Result, the Lab Analyst shall immediately, before initiating any repeat testing, or retesting take the following actions: report the results to the Lab Team Leader or Lab Manager; document findings; document obvious errors (e.g., spilling of solutions or incomplete transfer of sample or standard), if known; retain all original samples and test preparations, such as sample solutions, standard solutions, glassware, microbiological culture media, and reagents used in the analysis and subsequent investigation, to the extent possible, until the initial investigation is completed; and retain samples and associated test preparations, when possible, in a manner that ensures their integrity (e.g., refrigerated) until the test article receives a final disposition. Note: The Lab Team Leader shall determine if obvious errors (e.g., calculation or dilution errors) exist that might have caused the OOS or Questionable Result. If an obvious error is found, the OOS or Questionable Result is considered an invalidated result and no further investigation is required, unless the error would impact other testing. If obvious errors are not found, the Lab Team Leader shall initiate a further investigation The analyst ensures that an entry into the laboratory investigation database (online) or if this database is not available, an entry into the log book (manual system) is made and that a unique number is assigned to the laboratory investigation report. At this time, the analyst and team leader or designate completes section 1 (general information) of the laboratory investigation report. In cases where more than one lot of material is investigated for the same problem, only one investigation report is required. All affected lots must be clearly listed All Laboratory Investigation Reports are assigned a unique number. In cases where the online system is used, the number is assigned automatically by the database system and is denoted by the following format: (YYYYMMXXX, where YYYY and MM are representative of the computer system date s year and month respectively and XXX is uniquely allocated a sequential number applied based on the month and year. strictly prohibited. Page 3 of 11

4 In cases where a manual system is used, the number consists of a two-letter prefix (LI) followed by an eight-digit identification number. The format of the Laboratory Investigation Report number will be as follows: The first two digits of the identification number are the Department Number for the Laboratory in which the investigation was conducted. The department numbers are as follows: 10 = Analytical Services, 23 = Quality Control & Microbiology, 41 = Research & Development. The second two digits of the identification number indicate the year in which the Laboratory Investigation was conducted. The remaining four digits are assigned sequentially from the Laboratory Investigation log book for that laboratory with the numbering system starting anew at the beginning of the year. 5.2 Initial Investigation Within one business day, the analyst and the microbiologist must initiate a Microbiological Laboratory Investigation, completing the following sections of the Laboratory Investigation Report. Section I: Purpose of Investigation Section II: Reason For Investigation Section III: Initial Investigation Section IV: Findings/Conclusions from initial investigation All sections must be completed with appropriate detail to fully describe steps taken. If a section is considered not applicable to the investigation, i.e. assignable cause is readily apparent, mark the section "Not Applicable". Justification must be provided in Section IX: Overall conclusion from III, IV, V (if applicable), VI, VII After opening the LIR, the initial investigation to determine assignable cause begins when the Micro Team Leader holds discussions with the Lab Analyst and completes the LIR Form Section I General Information. Section I shall include a clear and concise description of the reason for the investigation. In cases where more than one lot of material is investigated for the same problem, only one LIR is required. All affected lots must be clearly listed. The initial investigation also includes but is not limited to examinations of the following (LIR Form Section II, Review of Testing Parameters ): Test records (raw data and/or laboratory notebooks); Test procedures used; Calculations; Dilution schemes; Instrumentation or equipment functionality; Reference Standards, reagents, and media used; Sample preparations; and Personnel training and qualifications. strictly prohibited. Page 4 of 11

5 5.2.3 If, in the Micro Team Leader s judgement, assignable cause is identified for an OOS or questionable result, the original result is invalidated. The assignable cause shall be documented in the LIR Form Section III Initial Investigation and Section IV Findings/Conclusions from Initial Investigation within one business day of discovery of the result. Testing is then repeated to generate valid results. 5.3 Assignable Cause The analyst completes Section VII of the Laboratory Investigation Report: Retest Protocol. The Microbiology Team Leader approves the retest protocol. Retest is conducted as per the approved protocol. The OOS or Questionable Result may be accepted as valid following the initial investigation with no further retesting. If there is no readily apparent assignable cause the investigational measurement protocol (IMP) (section V of the laboratory investigation report) is prepared and signed by the team leader or designate. The purpose of conducting investigational measurement is to determine an assignable cause. This section should only be completed when a suitable protocol is decided. Data generated during and investigational measurement is for investigation only and shall not be used as a valid test result On the Laboratory Investigation Report, the Micro Team Leader delegate/ completes Section VIII: Results of Retest, Section IX: Overall Conclusions and if corrective action is required, Section X: Corrective Action Plan. The potential impact on other samples tested during the initial testing must be evaluated when an assignable cause is found. All related test results must be assessed for validity. A statement documenting the assessment and the decision must be included on the LIR Form Section III Review of Testing Parameters, or Section IV Findings/Conclusions from Initial Investigation If, in the Lab Manager s judgment, no readily apparent assignable cause is determined by the initial investigation, it may be necessary to issue an Alert report to notify others of the situation. The Lab Manager shall determine whether an alert report is needed and notify the QA Manager that an alert report is needed. The QA Manager shall ensure that such reports are issued within one business day following the completion of Section IV of the LIR form Test Results, whether In- or Out-of-Specification, that are obtained under the following conditions must be invalidated and the test repeated. These are examples of the classifications that are included on the LIR Form to document types of assignable causes: Sample The original sample was contaminated or insufficient in quantity; Method/Documentation Unclear test method for Standard Operating Procedure directions which resulted in incorrect test execution; Analyst Error Examples include, but are not limited to: strictly prohibited. Page 5 of 11

6 - incorrect sample quantity used; - sample, sample solution, or standard spills; - dilution errors; or - improper test procedure; and Instrument/Mechanical/System Malfunction eg incubators. 5.4 Repeating the test (Assignable Cause Identified). All tests that were invalidated by establishment of an assignable cause are repeated. The repeat test result(s) shall replace the original invalidated results only. The original sample preparation(s) shall be used for this testing if: there is sufficient quantity of sample remaining to repeat the test; the assignable cause was not due to sample preparation; the sample preparations are stable and maintained under proper environmental conditions; and the sample or the sample preparations are not inadvertently contaminated LIR form Section VII Retest Protocol and Section VIII results of retest shall be used to document the repeat tests and the results obtained. The repeat /retest protocol shall be approved by Micro Team Leader prior to any repeat testing Microbial Limits Testing may be repeated for OOS or Questionable Results, using a 25gram sample for solids or 25 ml for liquids. 5.5 Retesting (No Assignable Cause Identified) A Retest Protocol LIR Form Section VII Repeat /Retest Protocol shall be approved by the Lab Team Leader prior to any retesting The retest protocol must be based on the specific problem identified, the history of the product, method, and batch/lot, any applicable compendial requirements, and must delineate the number of retests to be performed Where sample is available, retesting must be executed using the same sample set that was the source of the original OOS or Questionable Result, unless there is scientific rationale for not using the same sample. The rationale must be documented A control lot may be used to verify the accuracy of the analyses. The retest plan must specify acceptance criteria for the control lot. 5.6 Resample If evidence is provided that the original sample was contaminated, the material is re-sampled per approved sampling procedures and approval is required by QA Manager. If the approved sampling procedure is found to be the cause, an investigation must be initiated to assess the impact of the defective sampling technique on other batches. strictly prohibited. Page 6 of 11

7 5.6.2 Obtaining additional stability samples is permitted for confirmatory purposes. However, when possible, the sample that was the source of the initial OOS or Questionable Result must also be included in the retest plan All stability samples from the same packaging lot and stored under identical conditions are considered equivalent for the resample purposes. 5.7 Evaluation of results If an assignable cause is associated with the original OOS or Questionable Result, the original result is invalidated and the impact of the assignable cause on other samples in the test must be determined Data from the original sample shall be retained in the test record, invalidated, and not included in the batch disposition decision when an assignable cause has been established If no assignable cause is found to be associated with the original OOS, and retesting is performed, all test results shall be documented on the LIR, forwarded to the QA Manager, and considered in batch/lot release decisions If the test method is shown by investigation to be in question, a general review of the method must be conducted, and required corrective action taken. Corrective action is to be recorded on the LIR form. 5.8 Reporting Results Invalidated OOS Results shall not be averaged with retest results for reporting purposes LIR Form Section VIII Repeat/Retest Results shall be used to report results [i.e., the value determined to be the final valid results (e.g., the retest results, or the confirmed initial OOS)] Upon completion of the Laboratory Investigation for initial OOS results, the Laboratory Manager determines if the QA Manager needs to issue an Alert report A confirmed OOS microbiological test result shall result in rejection of the test article In the event of a confirmed OOS Result, it may be necessary to issue an alert report to other departments within the site to notify them of the situation. The QA Manager shall ensure that such reports are issued within one business day following confirmation of an OOS Result. The QA Manager shall also evaluate the need for an investigation into the source of the confirmed OOS result and ensure that such investigations are completed The QA Manager shall inform the Senior Management Team (QO Manager, Production Manager and the Operations Director) which shall determine if the issuance of any reports responsible for notifying the Area Quality Review Team (A-QRT) in the event of any proposed market Action (eg. Product Recall) or stop distribution notice. 5.9 Closing the Laboratory Investigation. strictly prohibited. Page 7 of 11

8 5.9.1 LIR Form Section IX Overall Conclusions, and if relevant, Section X Corrective Action Plan, shall be completed by the Lab Team Leader The Lab Manager and the QA Manager, using LIR Form Section XI Laboratory Investigation Report Approval, shall approve the completed LIR All LIRs must be completed and fully approved within 30 business days of the discovery of the initial OOS or Questionable Result. If the Laboratory Investigation will go beyond 30 business days, an interim status report must be issued by the Lab Manager to the QA Manager containing at least the following: The date of discovery of the OOS or Questionable Result, Summary of the LIR general information, Reason for the delay, Current status of the investigation, and Estimated date for completion of the LIR The Approved LIR shall be: considered part of the batch record; distributed as per Site procedures; and retained by the QA according to record retention policies LIR will be reviewed by the QA and QC Manager at least once per year to determine if trends are observed that require further corrective action. strictly prohibited. Page 8 of 11

9 LI Process Flowchart OOS or Questionable Result Detected Laboratory Team Leader Notified and LIR Raised if required NOTE 1: At any time during the LI, QA Manager may issue Alerts to principals potentially affected SEEK ASSIGNABLE CAUSE (AC) Review for obvious errors NOTE 2: Following Initial Investigation, the OOS or Questionable Result may be accepted as valid with no further investigational measurement or testing. AC Found? Yes Take Corrective Action No Conduct Initial Investigation Declare Original Results invalid AC Found? No Yes Repeat tests to replace initial result Is Resample needed? No Retesting Establish Retest Protocol and conduct retest Yes OOS Confirmed? No Report all test results to the QA Manager Obtain QA manager approval for resampling Yes QA Manager issues all required Alerts; and initiates any further required investigations Complete & Close LIR Form strictly prohibited. Page 9 of 11

10 6.0 DEFINITIONS / ACRONYMS 6.1 Microbiological Laboratory Investigation: The means by which the laboratory personnel document and investigate test results that do not conform to a predetermined specification or are questionable. The information is documented in a Microbiological Laboratory Investigation Report. The investigation shall be initiated when a questionable result or an Out of Specification (OOS) result has been identified. 6.2 Assignable Cause: The documented and scientifically justified explanation of the reason for an out of specification or questionable result. This is determined only after conducting a Microbiological Laboratory Investigation. 6.3 Assessment of Microbiological Contamination: In situations where raw material or finished product specifications are not clear as to whether an organism is objectionable, the significance of the micro -organism shall be assessed relative to the end product use, the nature of the product, and the potential hazard to the user The significance of the micro organism(s) isolated must be assessed encompassing the below listed criteria: 6.4 Questionable Result: The end product use. Nature of the finished product. Potential hazard to the user. Route of administration. Ability of the organism to degrade the product. Capacity of the product to support growth of the organism. Unusual or aberrant test results which do not involve an out of specification result. Examples of questionable results in a Microbiology Laboratory include: A pour plate method for determining the total aerobic microbial count using duplicate plates exhibited colonies on one plate in numbers that suggested the duplicate plate may not have contained the sample inoculum preparation Microbial Identification System identifies an organism for which an expected identification is not supported by the initial Gram stain morphology and confirmatory testing, or the probability of the identification based on the statistical confidence in the identification may be considered questionable and in need of further evaluation. strictly prohibited. Page 10 of 11

11 6.4.3 When serial dilutions are plated, higher number of CFU's are recovered from higher dilutions Micro-organism recovery is obtained on selective medium but no growth is obtained on non-selective medium, both coming from the same broth preparation. 6.5 Resample: A new sample obtained from previously sampled batch. 6.6 Retest: Additional testing on the original test sample. Re-testing is only appropriate after a Microbiological Laboratory Investigation has been completed, and where an assignable cause has been identified for an OOS result during a Microbiological Laboratory Investigation. 6.7 Out of Specification Result: A single determination of a test sample that does not conform to established specification. 6.8 Analyst Error Situations where OOS or questionable data are the result of a failure to comply with the approved procedure or an error during the analysis. Examples include the following; improper test procedure, contamination through the use of non-sterile equipment, media, diluents etc. 7.0 RELATED DOCUMENTS Form 690 Laboratory Investigation Report Form 8.0 SUMMARY OF CHANGES Version # MicLab-150 Revision History New strictly prohibited. Page 11 of 11

Laboratory OOS Investigations The Missing Link

Laboratory OOS Investigations The Missing Link Laboratory OOS Investigations The Missing Link India Pharmaceutical Alliance Carmelo Rosa, Psy.D Director Division of Drug Quality I November 6-17, 2017 Indian Pharmaceutical Alliance DISCLAIMER: The views

More information

GUIDE TO INSPECTIONS OF MICROBIOLOGICAL PHARMACEUTICAL QUALITY CONTROL LABORATORIES

GUIDE TO INSPECTIONS OF MICROBIOLOGICAL PHARMACEUTICAL QUALITY CONTROL LABORATORIES GUIDE TO INSPECTIONS OF MICROBIOLOGICAL PHARMACEUTICAL QUALITY CONTROL LABORATORIES Note: This document is reference material for investigators and other FDA personnel. The document does not bind FDA,

More information

Out of Specification & Out of Trend Investigations. October 2017

Out of Specification & Out of Trend Investigations. October 2017 Out of Specification & Out of Trend Investigations October 2017 How to use the Investigation Flowchart Navigation: Clicking on those Process Step boxes with a heavy border in a process flow will take you

More information

Manual 058 Out of Specification Results Investigation

Manual 058 Out of Specification Results Investigation 1 Purpose The purpose of this Guideline is to provide guidance for the investigation and response to Out of Specification (OOS) laboratory test results. 2 Scope and Applicability This Guideline applies

More information

CRITICAL ASPECT ANALYTICAL TEST REVIEW

CRITICAL ASPECT ANALYTICAL TEST REVIEW CRITICAL ASPECT ANALYTICAL TEST REVIEW Jakarta 14 December 2017 Speaker: HERU PURNOMO, ST QC WORK FLOW Start Sample Received (In-Process & Finished Good) Testing Review Lab Result Yes No Non Conformance

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union Ref. Ares(2014)968036-28/03/2014 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, 28 March 2014 EudraLex

More information

Good manufacturing practices

Good manufacturing practices ORIGINAL PAPER 1AR-10 ISBT Science Series (2009) 4, 6 10 Journal compilation 2009 International Society of Blood Transfusion Good manufacturing practices Blackwell Publishing Ltd A. Ahmed Quality Manager,

More information

Complaints Investigations Root Cause Analysis

Complaints Investigations Root Cause Analysis Complaints Investigations Root Cause Analysis Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does

More information

IDT Australia Ltd. 5/23/18

IDT Australia Ltd. 5/23/18 IDT Australia Ltd. 5/23/18 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS Warning Letter 320-18-55 Return Receipt Requested May 23, 2018 Dr. Graeme R. Kaufman CEO, Acting, and Chairman of the

More information

Handling OOS, OOT and Unexpected Results. Karen Ginsbury PCI Pharmaceutical Consulting Israel Ltd for IFF, October 2017

Handling OOS, OOT and Unexpected Results. Karen Ginsbury PCI Pharmaceutical Consulting Israel Ltd for IFF, October 2017 Handling OOS, OOT and Unexpected Results Karen Ginsbury PCI Pharmaceutical Consulting Israel Ltd for IFF, October 2017 What is an OOS What is an OOT What is an Unusual, Questionable, Atypical Result Objective:

More information

EudraLex. Part I1 Chapter 6: Quality Control

EudraLex. Part I1 Chapter 6: Quality Control EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines tofor Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use Part I1 Chapter 6: Quality

More information

OOS: Back to Basics. Compliant, Effective, Efficient PATH

OOS: Back to Basics. Compliant, Effective, Efficient PATH OOS: Back to Basics Even with the number of trainings, seminars, online webinars and consultant guided investigations, companies are still seeing FDA 483 observations around how they are handling and investigating

More information

LABORATORY COMPLIANCE

LABORATORY COMPLIANCE 1 LABORATORY COMPLIANCE Jeanne Moldenhauer Vectech Pharmaceutical Consultants, Inc. Farmington Hills, MI INTRODUCTION Implementation of the Systems-Based Inspection Guideline for drug manufacturers in

More information

Documenta tion and Records

Documenta tion and Records Documenta tion and Records Page 1 of 30 Training Outcome of the Module: After completing this module, you will be able to: Recognize the importance of procedures Recognize the importance of record keeping

More information

Overcome the Top Challenges of Handling OOS Results by Knowing FDA Observations

Overcome the Top Challenges of Handling OOS Results by Knowing FDA Observations Overcome the Top Challenges of Handling OOS Results by Knowing FDA Observations Jerry Lanese Ph.D. The Lanese Group, Inc. 2015 The Lanese Group, Inc. 1 Who decided you should come to this conference? On

More information

IQCP for Streamlined ID QC of Vitek 2

IQCP for Streamlined ID QC of Vitek 2 IQCP for Streamlined ID QC of Vitek 2 Facility: EXAMPLE Test System: Vitek 2 Commercial Identification System Test System Primary SOPs include: GENERAL PROCEDURES: Quality Control for AST Cards and Identification

More information

INVESTIGATE OOT AND OOS IN STABILITY STUDIES

INVESTIGATE OOT AND OOS IN STABILITY STUDIES INVESTIGATE OOT AND OOS IN STABILITY STUDIES Kim Huynh-Ba Executive Director Pharmalytik LLC www.pharmalytik.com BIOGRAPHY Kim Huynh-Ba has over 25 years of experience in analytical development, project

More information

Example # 2. IQCP for Antimicrobial Susceptibility Testing (AST) Test System: Beckman Coulter Microscan Walkaway 96. Facility: Written by: Date:

Example # 2. IQCP for Antimicrobial Susceptibility Testing (AST) Test System: Beckman Coulter Microscan Walkaway 96. Facility: Written by: Date: IQCP for Antimicrobial Susceptibility Testing (AST) Test System: Beckman Coulter Microscan Walkaway 96 Facility: Written by: Date: Implementation Date: This risk assessment and IQCP plan has been approved

More information

Contents. Contents (13) 1 Production (23)

Contents. Contents (13) 1 Production (23) 1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing

More information

Equipment cleaning and use record

Equipment cleaning and use record DOCUMENTATION Documentation is an essential part of the quality assurance system and, as such, should be related to all aspects of GMP. Its aim is to define the specifications for all materials and the

More information

MICROBIOLOGICAL BEST LABORATORY PRACTICES USP <1117>

MICROBIOLOGICAL BEST LABORATORY PRACTICES USP <1117> MICROBIOLOGICAL BEST LABORATORY PRACTICES USP MEDIA PREPARATION AND QUALITY CONTROL MAINTENANCE OF MICROBIOLOGICAL CULTURES LABORATORY EQUIPMENT LABORATORY LAYOUT AND OPERATIONS SAMPLE HANDLING

More information

A24 CALA Checklist for Microbiology Revision 4.1 February 16, 2018

A24 CALA Checklist for Microbiology Revision 4.1 February 16, 2018 A24 CALA Checklist for Microbiology Revision 4.1 February 16, 2018 Laboratory Name: Appendix Name: Appendix Number: Assessor: Date: Rev. 4.1 CALA CHECKLIST FOR MICROBIOLOGY Item 01 SAMPLING AND SAMPLE

More information

Quality Assurance Policy and Procedures

Quality Assurance Policy and Procedures 650 Montana Ave, Suite A Las Cruces, NM 88001 (575) 522-0430 www.rmgovernmentservices.com Quality Assurance Policy and Procedures PURPOSE. The purpose of this policy is to outline the quality assurance

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Seite 1 von 10 Inspections, Compliance, Enforcement, and Criminal Investigations Laboratoire Atlas Inc. 6/25/09 hhsbluebird Department of Health and Human Services Public Health Service Food and Drug Administration

More information

21CFR Ventilation, air filtration, air heating and cooling. 21CFR211 Details, Details. 21CFR Equipment Cleaning and Maintenance

21CFR Ventilation, air filtration, air heating and cooling. 21CFR211 Details, Details. 21CFR Equipment Cleaning and Maintenance 21CFR211 Details, Details Kirsten L. Vadheim, Ph.D., RAC 7710 196th Avenue N.E. Redmond WA 98053 Tel: 651.260.6560 Fax: 425.868.4302 klvadheim@hotmail.com 21CFR211.46 Ventilation, air filtration, air heating

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Seite 1 von 10 Inspections, Compliance, Enforcement, and Criminal Investigations Dabur Oncology PLC hhsbluebird Department of Health and Human Services Warning Letter Public Health Service Food and Drug

More information

Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel

Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active

More information

New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765

New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 Division of Environmental Health Sciences Albany, New York NYS DOH LEB-608 Identification

More information

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU

More information

Oklahoma Checklist (OK)

Oklahoma Checklist (OK) SubHeader : 01 General Information 001 Laboratory Name: OAC 252:301-1 002 Address: 003 Phone/Fax Number: 004 Date: 005 Primary POC: 006 Email/Website: 007 *Applicable to laboratories, which have performed

More information

IQCP for Commercially Prepared CLSI-Exempt Media

IQCP for Commercially Prepared CLSI-Exempt Media Please note that some references to protocol, publications, performance data etc. are fictitious in this EXAMPLE. Please use your own DATA for your IQCP. The following represents one example of how you

More information

New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765

New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 Division of Environmental Health Sciences Albany, New York NYS DOH LEB-612 Identification

More information

New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765

New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 Division of Environmental Health Sciences Albany, New York NYS DOH LEB-610 Identification

More information

Microbiology Testing: USP requirements for Sterile and Nonsterile Preparations Webinar Q&A

Microbiology Testing: USP requirements for Sterile and Nonsterile Preparations Webinar Q&A USP Antimicrobial Effectiveness Testing Microbiology Testing: Webinar Q&A 1. If a base ingredient is designed for the purpose of compounding a specific type of preparation does this forgo the necessity

More information

GUIDANCE NOTES ON ANALYTICAL METHOD VALIDATION

GUIDANCE NOTES ON ANALYTICAL METHOD VALIDATION ON ANALYTICAL METHOD VALIDATION HSA September 2004 Reproduction prohibited for commercial purposes. Reproduction for internal use is authorised, provided the source is acknowledged. MQA Dir: DISK1\GUIDE-MQA-012A-004.doc

More information

New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765

New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 Division of Environmental Health Sciences Albany, New York NYS DOH LEB-606 Identification

More information

Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines

Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines Review Article Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines Chagi Venkatesh*, S. B. Puranik ABSTRACT Good practices in quality control (QC) department

More information

3. Equipment Cleaning Validation for Active Pharmaceutical Ingredients (APIs) 8. Process Validation for Active Pharmaceutical Ingredients (API)

3. Equipment Cleaning Validation for Active Pharmaceutical Ingredients (APIs) 8. Process Validation for Active Pharmaceutical Ingredients (API) Title: Good Working Practice Validation Requirements Practice Number: 06 Prepared by: Date: Supersedes: Checked by: Date: Date Issued: Approved by: Date: Review Date: Topics: 1. Biological Test Methods

More information

Public Health Service Food and Drug Administration Silver Spring, MD WARNING LETTER VIA UPS WL:

Public Health Service Food and Drug Administration Silver Spring, MD WARNING LETTER VIA UPS WL: Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring, MD 20993 WARNING LETTER VIA UPS WL: 320-16-04 December 17, 2015 Mr. Avinash Joshi Quality Head

More information

Sun Pharmaceutical Industries Ltd. 12/17/15

Sun Pharmaceutical Industries Ltd. 12/17/15 1 of 7 02/18/2016 11:34 AM U.S. Food and Drug Administration Protecting and Promoting Your Health Sun Pharmaceutical Industries Ltd. 12/17/15 Department of Health and Human Services Public Health Service

More information

Public Health Service Food and Drug Administration Silver Spring, MD WARNING LETTER VIA UPS WL: December 17, 2015

Public Health Service Food and Drug Administration Silver Spring, MD WARNING LETTER VIA UPS WL: December 17, 2015 12/23/2015 1:37 PM 1 of 10 U.S. Food and Drug Administration Protecting and Promoting Your Health Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring,

More information

SQF Food Safety Code for Manufacturing Changes from Edition 7 to Edition 8

SQF Food Safety Code for Manufacturing Changes from Edition 7 to Edition 8 All changes are highlighted in yellow. SQF System Elements for Food Safety Code for Manufacturing Edition 7 Edition 8 Comments 2.1 Management Commitment 2.1 Management Commitment 2.1.1 Management Policy

More information

Correspondence Between ISO 13485:2016 and 21 CFR Part 820 QMS Requirements

Correspondence Between ISO 13485:2016 and 21 CFR Part 820 QMS Requirements Correspondence Between and 21 CFR Part 820 QMS Requirements 10411 Corporate Drive, Suite 102, Pleasant Prairie, WI 53158 262.842.1250 262.842.1240 info@rcainc.com rcainc.com 2 4 Quality Management System

More information

Page 1 of 26 Revision October 2001

Page 1 of 26 Revision October 2001 Page 1 of 26 Table of Contents Section Page No I. PURPOSE AND SCOPE... 3 II. AUTHORITY... 3 III. REFERENCE... 3 IV. RESPONSIBILITY... 3 V. POLICY... 3 VI. PROCEDURE... 4 A. Introduction... 4 B. Data Validation

More information

Registered Starting Material Auditing Guide

Registered Starting Material Auditing Guide Registered Starting Material Auditing Guide Annex 1 Aide Mémoire Company : Auditor(s) : Location, Country : Date of Audit: APIC Guide for Auditing Registered Starting Material Manufacturers Remark: Non-compliance

More information

9/2/15 (replaces 5/31/15 version) Page 1

9/2/15 (replaces 5/31/15 version) Page 1 Please note that some references to protocol, publications, performance data etc. are fictitious in this EXAMPLE. Please use your own DATA for your IQCP. The following represents one example of how you

More information

AAMI Quality Systems White Paper

AAMI Quality Systems White Paper AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017, Updated February 2018 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward,

More information

Document Review 1 2 3

Document Review 1 2 3 01 DOCUMENT CONTROL 01 4.3 The current authorized test method and (7.2.1.2) supporting work instructions are available to the analyst. 02 01 5.4 (7.2.1.5) TEST METHOD VERIFICATION/VALIDATION For standard

More information

New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765

New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 New York State Department of Health - Wadsworth Center Laboratory of Environmental Biology NYS ELAP Laboratory ID 10765 Division of Environmental Health Sciences Albany, New York NYS DOH LEB-607 Identification

More information

GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS

GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS Note: This document is reference material for investigators and other FDA personnel. The document does not bind FDA, and does no confer any

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 8 Inspections, Compliance, Enforcement, and Criminal Investigations Lupin Limited 5/7/09 Department of Health and Human Services Public Health Service Food and Drug Administration CENTER FOR

More information

OUT OF SPECIFICATION. SASIDA YOOSOOK 4 April 2014

OUT OF SPECIFICATION. SASIDA YOOSOOK 4 April 2014 OUT OF SPECIFICATION SASIDA YOOSOOK 4 April 2014 ISO 17025:2005 4.9 Control of nonconforming testing and/or calibration work 4.9.1 The laboratory shall have a policy and procedures that shall be implemented

More information

Nonconforming Material System Procedure

Nonconforming Material System Procedure Page: 1 of 13 Nonconforming Material System Procedure Page: 2 of 13 1.0 PURPOSE AND SCOPE 1.1 Purpose a. To define the system for identifying, segregating and controlling, and disposing of material, identified

More information

How to Handle Excursions in Environmental Monitoring (EM) and Personnel Monitoring (PM) in an Aseptic Processing Plant

How to Handle Excursions in Environmental Monitoring (EM) and Personnel Monitoring (PM) in an Aseptic Processing Plant How to Handle Excursions in Environmental Monitoring (EM) and Personnel Monitoring (PM) in an Aseptic Processing Plant Randy Hutt, Ph.D. Associate Director Sterility Assurance and Microbiology Luitpold

More information

NEW YORK STATE DEPARTMENT OF HEALTH CLINICAL LABORATORY EVALUATION PROGRAM. Crosswalk of Proposed Revision to General Systems Standards

NEW YORK STATE DEPARTMENT OF HEALTH CLINICAL LABORATORY EVALUATION PROGRAM. Crosswalk of Proposed Revision to General Systems Standards Any General Systems Standards not addressed here remain in effect. (changes are underlined) CURRENT STANDARD CURRENT GUIDANCE PROPOSED STANDARD PROPOSED GUIDANCE Quality Management System Sustaining Standard

More information

QUALITY AGREEMENT. This Quality Agreement is made between. (Customer Legal Entity Name Hereinafter called CUSTOMER ) And

QUALITY AGREEMENT. This Quality Agreement is made between. (Customer Legal Entity Name Hereinafter called CUSTOMER ) And QUALITY AGREEMENT This Quality Agreement is made between (Customer Legal Entity Name Hereinafter called CUSTOMER ) And (Pall Legal Entity Name Hereinafter called PALL ) 1. Table of Contents 1. Table of

More information

Hot Topics in Drug Product Process Validation: A Reviewer s Perspective

Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum

More information

Quality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines

Quality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines Human Journals Review Article January 2017 Vol.:8, Issue:2 All rights are reserved by Chagi Venkatesh et al. Quality Assurance in Pharmaceutical Biotech Industries as Per Regulatory Guidelines Keywords:

More information

CERTIFICATION SCHEME FOR TYPE APPROVAL OF PRODUCTS

CERTIFICATION SCHEME FOR TYPE APPROVAL OF PRODUCTS CERTIFICATION SCHEME FOR TYPE APPROVAL OF PRODUCTS 1. Introduction 1.1 Scheme for type approval of products of Indian Register of Shipping (IRS) is an impartial certification system based on a design review

More information

PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT

PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT August 2010 RESTRICTED PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT Please address any comments on this draft guideline

More information

IQCP for Disk Diffusion Antimicrobial Susceptibility Testing (AST)

IQCP for Disk Diffusion Antimicrobial Susceptibility Testing (AST) IQCP for Disk Diffusion Antimicrobial Susceptibility Testing (AST) Test System: Disk Diffusion Antimicrobial Susceptibility Testing (Kirby Bauer) / Twelve Disk Diffusion Test using BBL Disks Facility:

More information

TECHNICAL REQUIREMENTS (CLAUSE 5)

TECHNICAL REQUIREMENTS (CLAUSE 5) LECTURE 4 THE ELEMENTS OF ISO/IEC 17025 - TECHNICAL REQUIREMENTS (CLAUSE 5) Slide 1 ISO 17025 - RELATIONSHIP OF EACH REQUIREMENTS Management System Organization Quality system Continual Improvement Management

More information

Validation of Pharmaceutical Manufacturing Process Focus: APIs.

Validation of Pharmaceutical Manufacturing Process Focus: APIs. Validation of Pharmaceutical Manufacturing Process Focus: APIs Validations: Regulatory History (US FDA) Sterilisation 1977 Aseptic processing 1979 Water Systems 1981 Non-sterile Mfg Process 1987 Revised

More information

MANUAL QUALITY CONTROL & QUALITY ASSURANCE

MANUAL QUALITY CONTROL & QUALITY ASSURANCE MANUAL QUALITY CONTROL & QUALITY ASSURANCE METROTEC ENGINEERING LLC P.O. BOX: 26045, DUBAI U.A.E TEL : 043889771 FAX:043889772 E Mail: metrotecengg@yahoo.com info@metrotec.ae Web: www.metrotec.ae 2 TABLE

More information

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

USP Chapter 823 USP 32 (old) vs. USP 35 (new) USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has

More information

Erin Patton, MS Senior Product Specialist Charles River Labs, Microbial Solutions

Erin Patton, MS Senior Product Specialist Charles River Labs, Microbial Solutions Validation of a Rapid Microbial Method Approach to Validation Case Studies: Equivalence Verification of an Alternate Assay for Microbial Limits Screening and Sterility Testing of Pharmaceutical Products

More information

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould Good Manufacturing Practices Purpose and Principles of GMP Tony Gould Why GMP? Provides a high level assurance that medicines are manufactured in a way that ensures their safety, efficacy and quality Medicines

More information

Air Monitoring Directive Chapter 5: Quality System

Air Monitoring Directive Chapter 5: Quality System Air Monitoring Directive Chapter 5: Quality System Version Dec 16, 2016 Amends the original Air Monitoring Directive published June, 1989 Title: Air Monitoring Directive Chapter 5: Quality System Number:

More information

GMP The Other Side of Chemistry, Manufacturing & Controls (CMC)

GMP The Other Side of Chemistry, Manufacturing & Controls (CMC) Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls

More information

Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services

Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services Disclosures I, Ross Caputo, declare no conflicts of interest, real or apparent, and

More information

SIX ESSENTIAL WORKFLOW STEPS FOR PAPERLESS, AUTOMATED, END-TO-END ENVIRONMENTAL MONITORING

SIX ESSENTIAL WORKFLOW STEPS FOR PAPERLESS, AUTOMATED, END-TO-END ENVIRONMENTAL MONITORING WHITEPAPER SIX ESSENTIAL WORKFLOW STEPS FOR PAPERLESS, AUTOMATED, END-TO-END ENVIRONMENTAL MONITORING The consequences of microbiological contamination of drug products run the gamut from FDA warning letters

More information

NATO MUTUAL GOVERNMENT QUALITY ASSURANCE (GQA) PROCESS

NATO MUTUAL GOVERNMENT QUALITY ASSURANCE (GQA) PROCESS AQAP 2070 NATO MUTUAL GOVERNMENT QUALITY ASSURANCE (GQA) PROCESS AQAP 2070 (January 2004) I ORIGINAL Page blank II ORIGINAL AQAP 2070 NORTH ATLANTIC TREATY ORGANIZATION NATO STANDARDISATION AGENCY (NSA)

More information

National Shellfish Sanitation Program (NSSP) Guide for the Control of Molluscan Shellfish: 2017 Revision

National Shellfish Sanitation Program (NSSP) Guide for the Control of Molluscan Shellfish: 2017 Revision PUBLIC HEALTH SERVICE U.S. FOOD AND DRUG ADMINISTRATION OFFICE OF FOOD SAFETY SHELLFISH AND AQUACULTURE POLICY BRANCH 5001 CAMPUS DRIVE COLLEGE PARK, MD 20740-3835 TEL. 240-402-2151/2055/4960 FAX 301-436-2601

More information

Exercise 13 DETERMINATION OF MICROBIAL NUMBERS

Exercise 13 DETERMINATION OF MICROBIAL NUMBERS Exercise 13 DETERMINATION OF MICROBIAL NUMBERS Introduction When biologists discuss the growth of microorganisms (microbial growth), they are actually referring to population size rather than to the size

More information

Journal of Atoms and Molecules

Journal of Atoms and Molecules Review article Journal of Atoms and Molecules An International Online Journal ISSN 2277 1247 CLEANING VALIDATION IN PHARMACEUTICAL INDUSTRIES Abhishek Raj Senior R&D Officer, Quest Pharmaceuticals Pvt.

More information

Supersedes Division Name Revision No. 0 Export Division Page No. 1 of 9

Supersedes Division Name Revision No. 0 Export Division Page No. 1 of 9 Page No. 1 of 9 Control Status 1.0 Purpose To lay down a procedure for conducting GMP inspection and report writing for issue of Written Confirmation for for medicinal products for human. 2.0 Scope This

More information

Top Annual 483 Observations: The Cycle of Quality June 2017 Presented by: Susan Schniepp

Top Annual 483 Observations: The Cycle of Quality June 2017 Presented by: Susan Schniepp Top Annual 483 Observations: The Cycle of Quality June 2017 Presented by: Susan Schniepp 2016 Regulatory Compliance Associates Inc. Top Observation for 5 years Year Drugs #1 citation Device #1 citation

More information

Quality Manual. Quality Manual. Vera Bioscience / Anu Life Sciences. April 2018

Quality Manual. Quality Manual. Vera Bioscience / Anu Life Sciences. April 2018 Quality Manual Vera Bioscience / Anu Life Sciences April 2018 Page 1 of 15 TABLE OF CONTENTS Quality Manual Page 1. Company Overview 3 2. References 3 3. Exemptions, Alternatives and Variances 3 4. General

More information

Quality Manual. Index

Quality Manual. Index This quality policy manual is for the use of, its Clients, Vendors, and the appropriate Regulatory Agencies. Unauthorized duplication or transfer to others is prohibited. Index Authorization... 3 Introduction...

More information

Metrics in Microbiology Monitoring Practices

Metrics in Microbiology Monitoring Practices Metrics in Microbiology Monitoring Practices Crystal Booth, M.M. Masters of Microbiology from North Carolina State University Former Associate Director of Microbiology at Novartis Metrics in Microbiology

More information

POLYCRAFT INCORPORATED QUALITY MANUAL Quality Manual QM -10 Approval: D. Wheeler.

POLYCRAFT INCORPORATED QUALITY MANUAL Quality Manual QM -10 Approval: D. Wheeler. Polycraft, Inc. QM - 10 Title: Polycraft, Inc. Quality Manual Copy Approval: D. Wheeler This Quality Manual is the sole property of Polycraft, Inc. and intended for exclusive use by the organization. This

More information

SQF 2000 Code. 6th Edition AUGUST A HACCP-Based Supplier Assurance Code for the Food Manufacturing and Distributing Industries

SQF 2000 Code. 6th Edition AUGUST A HACCP-Based Supplier Assurance Code for the Food Manufacturing and Distributing Industries SQF 2000 Code A HACCP-Based Supplier Assurance Code for the Food Manufacturing and Distributing Industries 6th Edition AUGUST 2008 Safe Quality Food Institute 2345 Crystal Drive, Suite 800 Arlington, VA

More information

1.2. Timelines Batch Record comments must be documented immediately when event occurs.

1.2. Timelines Batch Record comments must be documented immediately when event occurs. Standard Operating Procedure Title: Quality Concerns Investigation Process Table of Contents 1. Batch Record Comments... 2 2. Deviation Report (DR)... 2 3. Cross Functional Investigations (CFI)... 3 4.

More information

ISTA Accreditation Standard for Seed Testing and Seed Sampling

ISTA Accreditation Standard for Seed Testing and Seed Sampling INTERNATIONAL SEED TESTING ASSOCIATION (ISTA) Secretariat, Zürichstrasse 50, 8303 Bassersdorf, CH-Switzerland Phone: +41-44-838 60 00, Fax: +41-44-838 60 01, Email: ista.office@ista.ch, http://www.seedtest.org

More information

Quality Risk Management

Quality Risk Management Quality Risk Management Audit Expectations and Observations Matthew Davis Lead Auditor Office of Manufacturing Quality, TGA CAPSIG 4 th May 2011 www.tga.gov.au 2 QRM - TGA Expectations and Observations

More information

Quality System Requirements for Suppliers

Quality System Requirements for Suppliers Quality System Requirements for Suppliers Page: 1 1. Scope 2. Purpose This procedure describes the minimum quality system requirements for suppliers. The purpose of this procedure is to provide for a uniform

More information

SESSION 14. Documentation Requirements and Management for Validation. 30 March Frits Vogt

SESSION 14. Documentation Requirements and Management for Validation. 30 March Frits Vogt Validation Services SESSION 14 Documentation Requirements and Management for Validation 30 March 2017 Frits Vogt fritsvogt@valserv.nl Content Documentation Requirements and Management for Validation I.

More information

Sterilization of health care products Microbiological methods. Part 1: Determination of a population of microorganisms on products

Sterilization of health care products Microbiological methods. Part 1: Determination of a population of microorganisms on products Provläsningsexemplar / Preview INTERNATIONAL STANDARD ISO 11737-1 Third edition 2018-01 Sterilization of health care products Microbiological methods Part 1: Determination of a population of microorganisms

More information

QP Supplier Quality Requirements Manual. Purchasing. Dearborn Inc. Revision: E Page 1 of PURPOSE

QP Supplier Quality Requirements Manual. Purchasing. Dearborn Inc. Revision: E Page 1 of PURPOSE Page 1 of 8 1.0 PURPOSE 1.1 The purpose of this manual is to have a single document which conveys the minimum quality requirements and manufacturing practices expected of suppliers for value added products

More information

MICROBIOLOGICAL ANALYSIS OF FOOD & FOOD PRODUCTS

MICROBIOLOGICAL ANALYSIS OF FOOD & FOOD PRODUCTS MICROBIOLOGICAL ANALYSIS OF FOOD & FOOD PRODUCTS By Angshuman Saha Assistant Director Export Inspection Agency-Mumbai, PTH & T Maheswara Rao Technical Officer Export Inspection Agency-Mumbai, PTH 1 Introduction

More information

GMP Requirements. Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP)

GMP Requirements. Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP) GMP Requirements Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP) 2016. ALL RIGHTS RESERVED. Outline GMP Procedures and standards

More information

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY  ISSN Review Article INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C

More information

Trinity College Dublin QP Forum 2017 Tuesday 25 th April

Trinity College Dublin QP Forum 2017 Tuesday 25 th April Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current

More information

Standard Operating Procedure Title: Handling of Media Diluents and Reagents in the Microbiology Laboratory

Standard Operating Procedure Title: Handling of Media Diluents and Reagents in the Microbiology Laboratory Standard Operating Procedure Title: Handling of Media Diluents and Reagents in the Microbiology Laboratory Department Micro Laboratory Document no MICLAB 160 Title Handling of Media Diluents and Reagents

More information

OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT

OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT PA/PH/OMCL (13) 113 2R Evaluation and Reporting of Results Core document Full document title and reference Evaluation and Reporting of Results

More information

Lessons from Pharmaceutical Laboratory related FDA Warning Letters

Lessons from Pharmaceutical Laboratory related FDA Warning Letters Lessons from Pharmaceutical Laboratory related FDA Warning Letters The Agilent Critical Compliance Seminar 2016 Ludwig Huber Ludwig_huber@labcompliance.com Overview FDA Inspections and reports GMP compliance

More information

On the Q&A to the Guideline for Common Technical Documents

On the Q&A to the Guideline for Common Technical Documents To: Public Health Bureau Prefectural Government Letter from PFSB/ELD 22 nd October 2001 From: Evaluation & Licensing Division, Pharmaceutical & Food Safety Bureau, The Ministry of Health, Labour and Welfare

More information

IQC In Microbiology Testing

IQC In Microbiology Testing IQC In Microbiology Testing Christina Oscroft Campden Technology Ltd Chipping Campden Glos UK Tel: 00 44 1386 842000 email: c.oscroft@campden.co.uk Microbiological results help appraise safety, quality

More information

Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer

Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT API Manufacturer WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer Part 1: General information Name of Manufacture Unit number

More information